TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: The Study of Metastatic Pancreatic Adenocarcinoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion criteria:~1. Patients must have cyto-/histologically confirmed, recurrent or metastatic adenocarcinoma of the pancreas (mPAC).~2. Patients must have no history of prior chemotherapy.~3. Patients with prior radiotherapy.~4. Patients' baseline ECOG performance status must be 2.~5. Patients' life expectancy must be 12 weeks or greater.~6. Patients' age must be 20 and 75.~7. Patients must have adequate bone marrow function.~8. Patients must have adequate liver and renal function.~9. All patients must be sign and give written informed consent.~Exclusion criteria:~1. Patients who have major abdominal surgery, radiotherapy.~2. Patients with central nervous system metastasis.~3. Patients with active infection.~4. Pregnant or breast-nursing women.~5. Patients with active cardiopulmonary disease.~6. Patients who have peripheral neuropathy \> Grade I.~7. Patients who have serious concomitant systemic disorders.~8. Patients who have other prior or concurrent malignancy.~9. Patients who are under biologic treatment for their malignancy.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Statin dose titration (Type: EXPERIMENTAL): SLOG regimen:~S-1 20-40 mg/m2/b.i.d., day 1-7;Leucovorin 20 mg/m2/b.i.d., day 1-7;Oxaliplatin 85 mg/m2 in 250 mL of D5W,given as 2-hour intra-venous infusion, day 1;Gemcitabine 800 mg/m2 in 250 mL of normal saline, given as fixed dose-rate infusion,day 1;After the administration of gemcitabine, the infusion line should be flushed with 20 ml of normal saline and then 50 ml of 5% glucose solution before the administration of oxaliplatin; Every 14 days, as one cycle.Prophylactic G-CSF or GM-CSF will not be allowed in this study. In case of grade 4 or complication neutropenia, patients may receive G-CSF according to the regulation of National Insurance Bureru treated with appropriate antibiotics. Therapeutic G-CSF may be used at the discretion of attending physicians.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of MK0859 in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia (MK-0859-011)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patient is between 18 and 75 years of age~* Patient can be on a stable diet for the study~* Patient has a stable weight for more then 6 weeks before the study and has not participated in a weight loss program~Exclusion Criteria:~* Patient has chronic heart failure or a history of heart disease~* Patient has blood, digestive, or central nervous system disorders~* Patient is pregnant or nursing~* Patient is HIV positive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study for Evaluation of Efficacy and Safety of SH L 749 to Indolent B-cell Non-Hodgkin's Lymphoma

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Platelet counts of \>/= 100,000/mm3~* Absolute neutrophil counts of \>/= 1,200/mm3~* Bone marrow involvement \< 25%~Exclusion Criteria:~* Patients who received hematopoietic stem cell transplantation, including bone marrow transplantation, peripheral blood stem cell transplantation, etc.~* Patients presenting with marked bone marrow hypocellularity (any suspected bone marrow hypocellularity should be confirmed by bone marrow biopsy)~* Patients with previous myocardial infarction within the past 1 year, with heart disease that requires treatment or with pulmonary dysfunction~* Patients with serious concomitant diseases (cardiac failure, renal failure, etc.)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 74 Years
- Healthy Volunteers: f

Study Arms:
- Arm 1 (Type: EXPERIMENTAL): None
- Arm 2 (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Donepezil in Mild to Moderate Alzheimer's Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients between 50 and 85 years of age.~2. Patients newly diagnosed as probable AD based on Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, Text Revision (DSM-IV-TR) criteria and National Institute of Neurologic and Communicative Disorders and Stroke-AD and Related Disorders Association (NINCDS-ADRDA) criteria; Mild to moderate AD with Mini-Mental State Examination (MMSE) 10-24, modified Hachinski ischaemic scale (MHIS)≤4, Activity of daily life scale (ADL)≥23, and Hamilton Depression Scale (HAMD) \<7.~3. MRI image supports the diagnosis of AD (medial temporal lobe atrophy, Fazekas scale of white matter lesions≤2 within 6 months prior to the screening).~4. 5mg daily of Donepezil for at least four weeks before the screening.~5. Patient with exclusive caregiver.~6. Patient should be ambulatory or ambulatory aided by a walker or cane.~7. With good eyesight and hearing, can cooperate with the examination and treatment.~Exclusion Criteria:~1. Patients with vascular dementia, other types of dementia or with other psychiatric or neurological disorders (e.g. delirium, depression, Parkinson's disease, etc.).~2. Patients with type I diabetes, obstructive lung disease or asthma, vitamin B12 or folic acid deficiency, thyroid dysfunction, severe liver or kidney dysfunction, severe cardiac insufficiency (congestive heart failure, myocardial infarction, sick sinus syndrome, II-III degree atrioventricular block or heart rate\<50 beats/minute \[bpm\]).~3. Epilepsy or head trauma resulting in unconsciousness that occurred in the two years prior to the screening.~4. Patients with hematologic diseases (such as anemia, granulocytes, leukemia, etc.), tumor, neoplasms within 2 years prior to the screening.~5. Patients with a history of alcohol dependence and drug abuse.~6. Patients with known hypersensitivity to medicines or foods;~7. Patients taking anticholinergic agents or antihistaminic agents;~8. Patients who had been hospitalized continuously for more than 3 months before the screening.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- donepezil (Type: OTHER): This is a multi-center single-arm study, which assess the safety and efficacy of donepezil in mild to moderate Alzheimer's disease in China.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Water Content in E-Liquids

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* at least 21 years old~* able to read/write~* \>/= 6 mths e-cig use~* regular e-cig use (\>/= 4 days/week)~* use of flavored e-cigs~* use of nicotine containing e-cigs~* urine cotinine \>/= 200ng/ml~* no plan to quit e-cig use~Exclusion Criteria:~* breastfeeding, pregnant, trying to become pregnant~* Medical conditions that increase risk of respiratory problems among participants~* Current use of illegal substances~* Medical conditions increasing risk of respiratory problems in nonpatient populations~* Current diagnosis of an untreated psychiatric condition~* Not fully vaccinated for Coronavirus-19

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Experimental E-Liquid Order A (Type: EXPERIMENTAL): All participants will be given all e-liquids (i.e. all 16 flavor\*water concentration combinations (4 flavors and four water concentrations)) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across the 2 visits). For each flavor condition, water order will be randomized.
- Experimental E-Liquid Order B (Type: EXPERIMENTAL): All participants will be given all e-liquids (i.e. all 16 flavor\*water concentration combinations (4 flavors and four water concentrations)) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across the 2 visits). For each flavor condition, water order will be randomized.
- Experimental E-Liquid Order C (Type: EXPERIMENTAL): All participants will be given all e-liquids (i.e. all 16 flavor\*water concentration combinations (4 flavors and four water concentrations)) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across the 2 visits). For each flavor condition, water order will be randomized.
- Experimental E-Liquid Order D (Type: EXPERIMENTAL): All participants will be given all e-liquids (i.e. all 16 flavor\*water concentration combinations (4 flavors and four water concentrations)) in this within subject cross-over design study. Participants will be randomized in the order in which they receive the flavor conditions (across the 2 visits). For each flavor condition, water order will be randomized.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Optimizing Vitamin D in the Elderly

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: None
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* age over 65~* medically stable~* residing in long-term care or assisted living~Exclusion Criteria:~* hypercalcemia or high risk for hypercalcemia~* active cancer or malignancy other than non-melanoma skin cancer~* severe renal disease (eGFR \<30 ml/mkin/M2)~* small bowel resection or intestinal bypass surgery~* hyperparathyroidism~* granulomatous disease~* clinically unstable (changes in medications or diagnoses within a month, hospitalizations, within 6 months)~* allergy to vitamin D

- Gender: ALL
- Minimum Age: 65 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- vitamin D3 800 IU/day (Type: EXPERIMENTAL): recommended daily dosage of 800 IU/day D3
- 2000 IU/day D3 (Type: EXPERIMENTAL): D3 2000 IU/day
- vitamin D3 4000 IU/day (Type: EXPERIMENTAL): D3 4000 IU/day
- 50,000 IU/week D3 (Type: EXPERIMENTAL): D3 50,000 IU weekly

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: NEP-TUNE: Neuropathic Pain - Treatment With Pregabalin Under Real-life Conditions in Denmark

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Subjects aged 18 years or over.~* Subjects diagnosed with peripheral neuropathic pain.~* Subjects that independently of the study and before consideration for observation in the study have been prescribed pregabalin for treatment of peripheral neuropathic pain either.~  1. for the first time ('first prescription patients') or~ 2. that have not used pregabalin within the previous 6 months but are prescribed pregabalin again ('re-treatment patients')~* Subjects that haven't taken the first dose of the prescribed pregabalin yet.~Exclusion Criteria:~* Subjects not consenting to participate.~* Subjects that at study inclusion (baseline) are on treatment with pregabalin for generalized anxiety or epilepsy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients with peripheral neuropathic pain treated with Lyrica (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Episodic Future Thinking and Weight-Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion:~* Child age between 10-14~* Child height and weight that calculates to a BMI above the 85th percentile (BMI in overweight/obesity range)~* Parent height and weight that calculates to a BMI above 18~* Possession of at least one electronic device (per family) with WiFi capabilities (e.g. smartphone, tablet, computer)~* Home internet access~* Motivation to lose weight~Exclusion:~* Disordered eating patterns (e.g. binge-eating disorder, extreme weight-loss behaviors)~* A family history of eating disorders (siblings, children, parents, or grandparents)~* Medical conditions that are known to interfere with weight-loss (e.g. type 1 diabetes, thyroid disease)~* Medical conditions that may affect their ability to use the computer for a prolonged period of time or follow study protocol~* Psychopathology or disabilities that would limit adherence to protocol (e.g. depression, suicidality, ADHD). Participant will only be excluded if the disability would not allow them to adhere to protocol. Just having the disability does not exclude them. Suicidality would be automatically be exclusionary)~* Substance use, abuse, or dependence (e.g. binge drinkers, illicit substance users, alcoholics)~* Plans to start or stop a medication that may affect appetite/weight-loss during the intervention period~* Have started a medication within 6 months that is affecting appetite/weight-loss~* Plans to move out of the area during the treatment period~* Pregnancy/breastfeeding or plans of becoming pregnant during the study period~* Is participating in another weight-loss program~* Can not successfully record eating behavior in the MyFitnessPal app~* A) Had bariatric surgery less than one year ago B) If the potential participant had bariatric surgery over a year ago, their weight has not been stable for at least 6 months

- Gender: ALL
- Minimum Age: 10 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Episodic Future Thinking Group 7-week baseline (Type: EXPERIMENTAL): The experimental group will receive the Episodic Future Thinking (EFT) intervention after a 7-week baseline. EFT teaches individuals to pre-experience events, or think prospectively, about future events as if they were happening now \[Atance\].
- Episodic Future Thinking Group 10-week baseline (Type: EXPERIMENTAL): The experimental group will receive the Episodic Future Thinking (EFT) intervention after a 10-week baseline. EFT teaches individuals to pre-experience events, or think prospectively, about future events as if they were happening now \[Atance\].

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: BI 655066 (Risankizumab) Compared to Placebo and Active Comparator (Ustekinumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion criteria:~* Male or female patients with age ≥18 years at screening.~* Have a diagnosis of chronic plaque psoriasis (with or without psoriatic arthritis) for at least 6 months before the first administration of study drug.~* Have stable moderate to severe chronic plaque psoriasis with or without psoriatic arthritis at both Screening and Baseline (Randomisation):~  1. Have an involved body surface area (BSA) ≥10% and~ 2. Have a Psoriasis Area and Severity Index (PASI) score ≥12 and~ 3. Have a static Physician Global Assessment (sPGA) score of ≥3.~* Must be candidates for systemic therapy or phototherapy for psoriasis treatment, as assessed by the investigator.~* Must be a candidate for treatment with Stelara® (ustekinumab) according to local label.~Exclusion criteria:~* Patients with:~  1. non-plaque forms of psoriasis (including guttate, erythrodermic, or pustular)~ 2. current drug-induced psoriasis (including an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)~ 3. active ongoing inflammatory diseases other than psoriasis and psoriatic arthritis that might confound trial evaluations according to investigator's judgment~* Previous exposure to BI 655066.~* Previous exposure to ustekinumab (Stelara®).

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Placebo (Part A) (Type: PLACEBO_COMPARATOR): Participants randomized to receive double-blind (DB) placebo by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
- Ustekinumab (Part A) (Type: ACTIVE_COMPARATOR): Participants randomized to receive double-blind (DB) ustekinumab 45 mg or 90 mg (based on screening weight) by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).
- Risankizumab (Part A) (Type: EXPERIMENTAL): Participants randomized to receive double-blind (DB) risankizumab 150 mg by subcutaneous (SC) injection at Weeks 0 and 4 (Part A).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Biatain Ibu vs. Biatain in Painful Chronic Venous Leg Ulcers

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* \>= 18 years of age~* Chronic venous leg ulcer on the lower leg~* Ulcer duration \>= 8 weeks~* Pain intensity in study ulcer at least 4 on an 11-point numerical box scale (NBS): 0= no pain, 10= worst possible pain~* Exudate level moderate to high~* Ulcer size min 1.6 cm and max 11 cm in any direction~* Ankle/brachial index \>= 0.8~* Treated with moist wound healing during the past 2 weeks prior to inclusion~* Adequate compression therapy during the past 2 weeks prior to inclusion~* The patient is cognitive capable of evaluating his/her pain relief and pain intensity~* The patient is able to understand the treatment and is willing to comply with the treatment regimen.~* The patient is able to complete the patient diary~* The patient is willing and able to give written informed consent~Exclusion Criteria:~* Painful ulcers that have been treatment resistant to analgesics for the past 6 months or more~* Pregnant or lactating women~* Known and verified hypersensitivity to any content of the products used in this investigation~* Local infection (bacterial imbalanced wound) in the study ulcer~* Clinical infection in the study ulcer~* Diseases: Vasculitis, erysipelas and cellulitis of the peri-ulcer skin~* The investigator considers the patient not eligible~* Diseases and conditions where ibuprofen or other analgesics are contraindicated (including known hypersensitivity to Aspirin (acetylsalicylic acid) or other analgesics, especially associated with a history of asthma, rhinitis or urticaria)~* Diabetes~* Use of per need medication for the past 3 days~* Concomitant treatment with systemic antibiotics other than nitrofurantoin~* Concomitant treatment with systemic corticosteroids (more than 10 mg/day prednisolon or equivalent) or other immunosuppressants within 1 month prior to inclusion~* Concomitant treatment with cancer chemotherapeutics~* Concomitant participation in other studies~* Previous participation in this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Biatain Ibu (Type: EXPERIMENTAL): Biatain Ibu
- Biatain (Type: ACTIVE_COMPARATOR): Biatain

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete